10/16/2024
We are proud to present the full report from the April 2024 meeting, Health eMatters IMPACT: Promoting Equity Diversity and Inclusion in Clinical Trial Accruals, held in Toronto. Read full report here:https://support.myeloma.ca/site/DocServer/HeM_IMPACT_report_2024_1__1_.pdf
Without zeroing in on one specific community, situation, or disease type, the goals of the meeting were to:
1) take a bird’s eye approach to trial operations;
2) identify one to two process shortcomings that can have a negative impact on trial participation; and
3) workshop change management strategies through a design-thinking approach.
Ultimately, the findings from the meeting are intended to serve as a blueprint for a model project to integrate EDI in all institutions performing clinical trials and sponsors/researchers designing trials. As next steps, a follow up meeting entitled Phase 0 is scheduled to take place in March 2025. The goal of the next meeting will be to bring all key decision-makers to the table to workshop/design a clinical trial model in consideration of the Health eMatters IMPACT outcomes.
We would like to thank J&J Innovative Medicines, AbbVie, Pfizer and Bristol Myers Squibb for supporting this initiative and for their foresight and enthusiasm in exploring new ways to collaborate with patient advocates and multi-disciplinary partners to improve clinical trial practices in Canada, and beyond.
Thank you also to the esteemed speakers for providing fantastic perspectives and background information, the Health eMatters IMPACT steering committee (Yelak Biru, Alvina Nadeem, Judy Needham, and Dawn Richards), for helping to shape an impactful agenda, and to Alvina Nadeem for leading a successful HCD workshop with tangible outcomes.
Enjoy the read and looking forward to connecting with you on future collaborations!